Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer - PubMed (original) (raw)
Case Reports
doi: 10.1159/000197876. Epub 2009 Feb 3.
Affiliations
- PMID: 19188744
- DOI: 10.1159/000197876
Case Reports
Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer
Juan Javier Lammoglia et al. Horm Res. 2009.
Abstract
Hyperphosphatemic familial tumoral calcinosis (HFTC) is an uncommon disease characterized by periarticular calcifications produced by the deposition of amorphous extraosseous calcifications of hydroxyapatite. It is associated with hyperphosphatemia due to increased tubular phosphate reabsorption, despite normal renal function and normal plasma PTH levels. The disease can be caused by inactivating mutations in either the fibroblast growth factor 23 (FGF23) gene, the UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) gene or in human KLOTHO (KL) gene. Herein, we describe a Caucasian 3-year-old girl with tumoral calcinosis who presented with elevated serum phosphorus levels and a large calcified mass at her left elbow which led to ulceration of the skin. Treatment with the phosphate binder sevelamer and the carbonic anhydrase inhibitor acetazolamide successfully reduced the serum phosphate levels and led to a reduction of the calcified mass. This medical management has not been described previously. Her 7-month-old sister also had elevated serum phosphate levels, but did not have ectopic calcifications. Sequencing analysis revealed a novel homozygous FGF23 missense mutation (c.367G>T, p.Gly123Trp) in both siblings while the parents were carriers of the mutation.
Copyright 2009 S. Karger AG, Basel.
Similar articles
- Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G, Price HE, Shore RM, White KE, Langman CB. Finer G, et al. Am J Med Genet A. 2014 Jun;164A(6):1545-9. doi: 10.1002/ajmg.a.36476. Epub 2014 Mar 25. Am J Med Genet A. 2014. PMID: 24668887 - Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Claramunt-Taberner D, Bertholet-Thomas A, Carlier MC, Dijoud F, Chotel F, Silve C, Bacchetta J. Claramunt-Taberner D, et al. Pediatr Nephrol. 2018 Jul;33(7):1263-1267. doi: 10.1007/s00467-018-3945-z. Epub 2018 Mar 28. Pediatr Nephrol. 2018. PMID: 29594503 - The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE. Garringer HJ, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):4037-42. doi: 10.1210/jc.2006-0305. Epub 2006 Jul 25. J Clin Endocrinol Metab. 2006. PMID: 16868048 - Hyperphosphatemic Familial Tumoral Calcinosis.
Ramnitz MS, Gafni RI, Collins MT. Ramnitz MS, et al. 2018 Feb 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2018 Feb 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 29389098 Free Books & Documents. Review.
Cited by
- Clinical Characteristics, Therapeutic Options, and Outcomes in Hyperphosphatemic Tumoral Calcinosis: A Systematic Review.
Cherian KE, Cherian J, Vinodhini D, Paul TV. Cherian KE, et al. Calcif Tissue Int. 2024 Sep;115(3):215-228. doi: 10.1007/s00223-024-01247-8. Epub 2024 Jul 1. Calcif Tissue Int. 2024. PMID: 38951179 Review. - Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
Sowaity ZA, Saleem JY, Sabooh TN, Dukmak ON, Abu Al-Saoud SY. Sowaity ZA, et al. Cureus. 2024 Mar 5;16(3):e55575. doi: 10.7759/cureus.55575. eCollection 2024 Mar. Cureus. 2024. PMID: 38576700 Free PMC article. - Venous Thrombosis in a Pseudohypoparathyroidism Patient with a Novel GNAS Frameshift Mutation and Complete Resolution of Vascular Calcifications with Acetazolamide Treatment.
Seven Menevse T, Iwasaki Y, Yavas Abali Z, Gurpinar Tosun B, Helvacioglu D, Dogru Ö, Bugdayci O, Cyr SM, Güran T, Bereket A, Bastepe M, Turan S. Seven Menevse T, et al. Horm Res Paediatr. 2024;97(4):404-415. doi: 10.1159/000534456. Epub 2023 Oct 31. Horm Res Paediatr. 2024. PMID: 37906994 - Canakinumab in addition to phosphate-binding and phosphaturia-inducing therapy were effective in achieving remission in a child with a large familial calcinotic tumour.
Ochoa M, Jurencak R, Smit K, Carsen S, Sawyer SL, Robinson ME, Khatchadourian K, Cheng HP, Pagé M, Werier J, Ward LM. Ochoa M, et al. Bone Rep. 2023 Jun 15;19:101695. doi: 10.1016/j.bonr.2023.101695. eCollection 2023 Dec. Bone Rep. 2023. PMID: 37520934 Free PMC article. - Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
Boyce AM, Lee AE, Roszko KL, Gafni RI. Boyce AM, et al. Front Endocrinol (Lausanne). 2020 May 8;11:293. doi: 10.3389/fendo.2020.00293. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32457699 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical